UniQure NV has secured a gene therapy agreement with Bristol-Myers Squibb Company in cardiovascular disease, its first major commercial deal since winning regulatory approval in 2012 for Glybera, a gene therapy for lipoprotein lipase deficiency. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Regenerative Medicine
